Background: Candida infections are among the most common fungal infection affecting immunocompromised patients in various disciplines of the health care system. In recent decades, due to dramatic increase in invasive fungal infections and related more common use of the antifungal therapy, resistance to antifungal agents has become an issue. Objectives: To determine the prevalence of candida species in various clinical specimen & their resistance to azole group of antifungal agents. Materials & Methods: This study was conducted at tertiary care hospital during January 2014 to June 2015. Total 23,896 samples (urine, blood, high vaginal swabs, oropharyngeal swab, body fluid, corneal scrapping, etc) were received over study period. Result: Out of total 8864 culture positive specimen, candida species were isolated in 644 specimens. Among total 644 Candida isolates, C.albicans is the most prevalent species (44%). Amphotericin B (99.6%) had the maximum rate of susceptibility amongst all the antifungal agents, followed by Voriconazole with 94.8% susceptibility. Fluconazole, Itraconazole & Miconazole were 73.3%, 73.44% & 74.22% susceptible respectively. Conclusion: Azole derivatives represent one of the major groups of antifungal drugs used in clinical practice to treat fungal infections. Empirical usage of Fluconazole in immune-compromised patients appeared to have played a major role in rising emergence of non albicans species resistant to Fluconazole.